Apimeds Pharmaceuticals Financials - Benzinga

Apimeds Pharmaceuticals Us Inc

APUSAMEX

Trade with Public

Trade with Public

$4.92

2.63114.85%

In chiusura: Sep 24, 5:00 PM EST

$5.72

0.8016.22%

Post-mercato: 7:59 PM EST

PRO

Perché si muove?:Apimeds Pharmaceuticals shares are trading higher after the company announc...

Panoramica Notizie Previsioni utiliDati finanziariSentiment Azionariato Confronta Rapporto azionario

Apimeds Pharmaceuticals Financials

Apimeds Pharmaceuticals (APUS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Apimeds Pharmaceuticals Q1 EPS $(2.26) Down From $(0.50) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(2.26) per share. This is a 352 percent decrease over losses of $(0.50) per share from the same period last year.

Benzinga Newsdesk

PRO
Apimeds Pharmaceuticals Q4 EPS $(0.80) Down From $(0.50) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(0.80) per share. This is a 60 percent decrease over losses of $(0.50) per share from the same period last year.

Benzinga Newsdesk

PRO
Apimeds Pharmaceuticals Q2 EPS $(0.26) Down From $(0.06) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(0.26) per share. This is a 333.33 percent decrease over losses of $(0.06) per share from the same period last year.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved